ArticleJournal of family medicine and primary care2023
Antibody titres in fully vaccinated healthcare workers with and without breakthrough infection during the Delta and Omicron waves.
Article in Journal of family medicine and primary care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Re: "Antibody titres in workers with and without breakthrough infection during the Delta and Omicron waves".Journal of family medicine and primary care · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Assessment of antibody response to vaccination against SARS CoV2 has clinical, public health, and policy implications during the pandemic and in the context of future waves. Method: In this repeated cross-sectional study, we estimated total binding antibody levels to the spike protein of the SARS CoV2 virus post two doses of Covishield vaccine among 133 health care workers (HCWs) (phase 1), followed by antibody levels among a subset ( Results: We report 100% seroconversion post 28 days of the second dose of the Covishield vaccine among infection naïve HCWs. In this study, 33% had a breakthrough infection in phase 1 and 24% reported a history of infection in phase 2. The antibody titres were higher in the breakthrough infection group compared to the infection naïve group during both Delta and Omicron waves. Conclusion: This shows that there is a good seroconversion with two doses of vaccine, weaning of antibody with time, and a rise of antibody titre if infected with SARS CoV 2 subsequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.